• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral antiplatelet therapy for acute ischaemic stroke.
CONCLUSIONS: Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved. PMID: 24668137 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 26, 2014 Category: Journals (General) Authors: Sandercock PA, Counsell C, Tseng MC, Cecconi E Tags: Cochrane Database Syst Rev Source Type: research

Oral antiplatelet therapy for acute ischaemic stroke
CONCLUSIONS: Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, significantly decreased death and dependency, and reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved.PMID:35028933 | DOI:10.1002/14651858.CD000029.pub4
Source: Cochrane Database of Systematic Reviews - January 14, 2022 Category: General Medicine Authors: Jatinder S Minhas Tamara Chithiramohan Xia Wang Sam C Barnes Rebecca H Clough Meeriam Kadicheeni Lucy C Beishon Thompson Robinson Source Type: research

Clinical predictors of fever in stroke patients: relevance of nasogastric tube
ConclusionsIn patients with acute stroke, four clinical variables were found to be independently associated with the risk of developing fever and, of them, nasogastric tube was the strongest and most significant one.
Source: Acta Neurologica Scandinavica - February 18, 2015 Category: Neurology Authors: A. Muscari, G. M. Puddu, C. Conte, R. Falcone, B. Kolce, M. V. Lega, M. Zoli Tags: Original Article Source Type: research

E-048 Factors Associated with Early Tracheostomy and Percutaneous Gastrostomy and Their Effects on Hospitalization in Hemorrhagic Stroke Patients
ConclusionsHemorrhagic stroke is a devastating neurovascular event that requires prompt intervention and vigilant management. Our study identified patient risk factors that may suggest candidacy for tracheotomy and PEG. Additionally, we found that timing of PEG may shape a patient’s hospital course. Complication rates related to tracheostomy and PEG in this population were minimal. In conclusion, this retrospective data set supports some benefit to early PEG placement in this population, and justifies the need for further prospective study.DisclosuresM. McCann: None. J. Fraser: None.
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: McCann, M., Fraser, J. Tags: Electronic poster abstracts Source Type: research

Disability and mortality after permanent feeding tube placement in patients with acute stroke (P3.107)
Conclusions:In our large cohort of patients with acute stroke and PEG tubes, nearly 9/10 had severe disability at discharge. From discharge to 1 year, there was no difference in mortality between PEG and NG patient cohorts. These results suggest that PEG tubes serve mainly to prolong survival in patients discharged with severe disability. Our study may help support guideline creation and facilitate discussions with patients and families regarding PEG tube placement after acute stroke.Disclosure: Dr. Joundi has nothing to disclose. Dr. Saposnik has nothing to disclose. Dr. Martino has nothing to disclose. Dr. Fang has nothi...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Joundi, R., Saposnik, G., Martino, R., Fang, J., Giannakeas, V., Porter, J., Kapral, M. Tags: Cerebrovascular Disease and Interventional Neurology Poster Discussion Session Source Type: research

E-008 Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting
ConclusionsEptifibatide may have a role in the management of acute stroke requiring carotid stenting. Caution may be required in those with established infarct on presentation imaging.Disclosures M. Waters: None. J. Vargas: None. R. Turner: None. A. Turk: None. I. Chaudry: None.
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Waters, M., Vargas, J., Turner, R., Turk, A., Chaudry, I. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting
CONCLUSIONS: Eptifibatide may have a role in the management of acute stroke requiring carotid stenting. Caution may be required in those with established infarct on presentation imaging.PMID:37574792 | DOI:10.1177/15910199231193928
Source: Interventional Neuroradiology - August 14, 2023 Category: Radiology Authors: Michael J Waters Jan Vargas Aquilla Turk Imran Chaudry Raymond D Turner Source Type: research

The Outcome of Status Epilepticus and Long-Term Follow-Up
Conclusion: This study highlights the importance of regular care and patient follow-up. Introduction Status epilepticus (SE) is a condition and most extreme form of epilepsy (1), which leads to abnormal and prolonged seizure (at least 5 min). In case SE persists over 30 min, it may have severe long-term consequences (2). Referring to the new classification scheme of SE, there are two operational dimensions of the definition: time point 1 (T1) is associated with abnormally prolonged seizure, when therapy should be initiated, while time point 2 (T2) is related to the time of on-going seizure activity involving a risk...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

In Process Citation.
Abstract Management of ischemic stroke is targeted on four therapeutic objectives: limitation of neurological deficit, prevention of earyl stroke recurrence, protection against complications, and secondary prevention. Intravenous thrombolysis within 4.5h of stroke onset is the only proven therapy to improvefunctional outcome. Although promising, neither endovascular recanalisation nor neuroprotective strategies have demonstrated efficacy so far. Immediate administration of antiplatelet agents like acetylsalicylic acid and clopidogrel - in case of intravenous thrombolysis at the earliest after 24h - is effective to...
Source: Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS - June 1, 2014 Category: Intensive Care Authors: Görtler M, Oldag A, Brejova A Tags: Anasthesiol Intensivmed Notfallmed Schmerzther Source Type: research

Monitoring of hospital acquired pneumonia in patients with severe brain injury on first access to intensive neurological rehabilitation: First year of observation.
Authors: Beghi G, De Tanti A, Serafini P, Bertolino C, Celentano A, Taormina G Abstract Nosocomial or hospital acquired pneumonia (HAP) is an illness contracted during a hospital stay, generally with onset 48 hours or more after admission to hospital, or within 14 days of discharge from hospital. HAP is divided into subgroups: Ventilator-associated pneumonia (VAP), accounting for 86% of hospital acquired pneumonia, and stroke-associated pneumonia (SAP). The incidence of SAP in neurological intensive care units (NICUs) is 4.1-56.6%, in medical intensive care units (MICUs) it is 17-50%, in stroke units it is 3.9-44% ...
Source: Monaldi Archives for Chest Disease - May 11, 2018 Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research

All bleeding stops — but does idarucizumab (Praxbind) make it stop faster?
3.5 out of 5 stars Persistent life-threatening hemorrhage after administration of idarucizumab. Alhashem HM et al. Am J Emerg Med 2016 June 30 [Epub ahead of print] Reference Dabigatran (Pradaxa) is a direct thrombin inhibitor approved for stroke and embolism prophylaxis in patients with non-valve-related atrial fibrillation. When it was first released in 2008, a major disincentive to widespread use was the lack of a reliable reversal agent to treat major bleeds, or to administer before necessary invasive procedures. In October 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind), a monoclonal ant...
Source: The Poison Review - July 27, 2016 Category: Toxicology Authors: Leon Gussow Tags: Medical anticoagulant hemorrhage idarucizumab pradaxa praxbind reversal agent Source Type: news

Pages: 1  2